Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Anixa Biosciences breast cancer vaccine featured in Daily Mail article

A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper. Anixa’s CEO, Amit Kumar, Ph.D., described the...

July 17, 2023

Developments

Ondine receives TAYYABA HASAN IMPACT AWARD at IPA World Congress

Ondine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Finland for demonstrating “exceptional perseverance and clinical...

July 17, 2023

Developments

Athira presents biomarker data in Alzheimer’s

Athira Pharma (NASDAQ:ATHA) is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system at the Alzheimer’s Association International...

July 17, 2023

Executive Moves

Veteran investment banker Jed Cohen joins Raymond James

Seasoned investment banker Jed Cohen has joined Raymond James as a managing director of its healthcare investment banking practice. The strategic hire underscores the firm’s continuing commitment to expanding the sector...

July 14, 2023

Developments

First Wave BioPharma unlikely to hit primary endpoint in CF

First Wave BioPharma’s (NASDAQ:FWBI) is unlikely to achieve the primary endpoint based on preliminary results from the Phase 2 SPAN study for the treatment of exocrine pancreatic insufficiency in patients with cystic...

July 13, 2023

Developments

FDA clears Tryp’s IND for Phase 2a IBS study at MGH

The FDA completed a review of Tryp Therapeutics’ (CSE:TRYP; OTCQB:TRYPF) investigational new drug application, permitting the company to proceed with a Phase 2a clinical trial at Massachusetts General Hospital (MGH)...

July 13, 2023

Developments

Theratechnologies reduces R&D headcount on sales shortfall

With sales falling short of expectations, Theratechnologies (TSX:TH; NASDAQ:THTX) is reducing its R&D head count. Second quarter revenue fell 8.9% to $17.5-million (U.S.) from $19.3-million a year ago. “Second...

July 12, 2023

Executive Moves

Former Pfizer vaccine president Nanette Cocero joins PharmaJet board

PharmaJet appointed Nanette Cocero, Ph.D., a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background, to the...

July 12, 2023

Developments

Synlogic gets FDA fast track to treat phenylketonuria

The FDA granted fast track designation to Synlogic’s (NASDAQ:SYBX) labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria (PKU). Labafenogene marselecobac also has received rare...

July 11, 2023

Developments

Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology

The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...

July 11, 2023

Developments

MAIA updates survival data from Phase 2 NSCLC trial

MAIA Biotechnology (NYSEA: MAIA) updated preliminary survival data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial, evaluating THIO in sequential combination with cemiplimab in patients with advanced...

July 10, 2023

Developments

ZyVersa receives European patent for VAR 200 in kidney disease

The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. “Approval of this...

July 7, 2023

General

More